InvestorWire NewsRoom

Press Release

PaxMedica Announces 1-for-17 Reverse Stock Split
October 30, 2023

PaxMedica Announces 1-for-17 Reverse Stock Split

TARRYTOWN, N.Y. , Oct. 30, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD), a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (APT) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms, today announced that as a result of its 1-for-17 reverse stock split of its common stock that became effective at 8:03 a.m. Eastern Time on October 30, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market on October 31, 2023. PaxMedica’s common stock will continue to trade under the existing trading symbol “PXMD.” The new CUSIP number for the common stock following the reverse stock split is 70424C 203.

As a result of the reverse stock split, each 17 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record who would otherwise have been entitled to receive a fractional share received a number of shares rounded up to the next whole share in lieu of fractional shares.

Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Computershare Trust Corporation, N.A. Computershare can be reached at (800) 564-6253 or by email at [email protected].

For additional information regarding the reverse stock split, please refer to PaxMedica’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 30, 2023.

About PaxMedica

PaxMedica is a clinical stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (“APT”) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including Autism Spectrum Disorder (“ASD”), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (“ME/CFS”), a debilitating physical and cognitive disorder. One of PaxMedica’s primary points of focus is the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and the advancing the clinical understanding of using that agent against other disorders such as ME/CFS. For more information, visit www.paxmedica.com.

Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at www.paxmedica.com/email-alerts and by following PaxMedica on Twitter, YouTube and LinkedIn

Contacts

PaxMedica, Inc.
303 S Broadway,
Suite 125.
Tarrytown, NY 10591
www.paxmedica.com

Media Contact
[email protected]
Investor Contact
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
[email protected]
www.paxmedica.com/investors

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).